ADMA Biologics rises after rejecting short-seller report

Shares of biotech firm ADMA Biologics ADMA.O rise about 3% to $11.63 premarket

ADMA rejects a negative report by Culper Research, which has a short position in the stock

Culper on March 24 accused the company of inflating its sales figures by pushing excess inventory onto distributors

ADMA says the report is based on “speculative assertions” and “unreliable sources” and includes misleading and false statements

Adds it is reviewing the claims and remains committed to accurate financial reporting and U.S. regulatory compliance

ADMA makes plasma-based medicines for people with weak immune systems

Shares rose ~6% in 2025